Clinical Trial Update: Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. [Phase 2]

View source ↗

Summary

This document describes a Phase II trial of S101 autologous anti-CD7 CAR-T cells for relapsed/refractory T lymphoblastic leukemia/lymphoma. The study status ind…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-lymphoblastic Leukemia
• T-lymphoblastic Lymphoma

Drugs mentioned

• S101 autologous anti-CD7 CAR-T cells (autologous anti-CD7 CAR-T cells)

Snippet

Sponsor: Hebei Senlang Biotechnology Inc., Ltd. | Conditions: T Lymphoblastic Leukemia/Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING